Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist
Background In contrast to immune checkpoint inhibitors, the use of antibodies as agonists of immune costimulatory receptors as cancer therapeutics has largely failed. We sought to address this problem using a new class of modular synthetic drugs, termed tumor-targeted immune cell agonists (TICAs), b...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
BMJ Publishing Group
2021-01-01
|
| Цуврал: | Journal for ImmunoTherapy of Cancer |
| Онлайн хандалт: | https://jitc.bmj.com/content/9/1/e001762.full |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
